Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if ...

About 1 in 10 people have diabetes, and 1 in 5 don’t even know they have | This week on "Podnosis," Yumlish CEO Shireen ...

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug ...

"With the FDA announcing the resolution of shortages for Semaglutide (Wegovy, Ozempic) and Tirzepatide (Zepbound, Mounjaro), compounding pharmacies must halt production of these medications. This ...

The Centre is taking a host of steps to increase self-sufficiency. In October 2024, the Union cabinet approved the National ...

Latest approval expands Medtronic CGM portfolio in the U.S. GALWAY, Ireland, April 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced ...

Spending on Ozempic, Wegovy and other similar prescriptions soared 500 percent in five years, according to a research letter.

Medtronic plc has announced the U.S. Food and Drug Administration (FDA) has approved the Simplera Sync sensor for use with ...

Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...

The once-daily pill, currently under investigation, is being studied for adults with type 2 diabetes who are not on any anti-diabetic medication and have been managing their condition through diet and ...

Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, ...

EYLEA ® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion ...